GlassScriptPhysician profile
Narinder K Malhotra
NPI 1942207337
$1,393.25
in general payments reported to CMS, 2019-2025
26 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $133 · 2021: $195 · 2022: $202 · 2023: $367 · 2024: $43.28 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $320.76 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $150.32 | 2019-2025 | Opdivo |
| Incyte Corporation | $117.72 | 2020-2025 | Niktimvo, Jakafi |
| Merck Sharp & Dohme LLC | $102.16 | 2019-2025 | Keytruda, Reblozyl |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Rigel Pharmaceuticals, INC. | $81.60 | 2022-2023 | Tavalisse, Rezlidhia |
| Eisai INC. | $52.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $37.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.67 | 2021-2024 | Calquence |
| Karyopharm Therapeutics INC. | $35.56 | 2021 | |
| Sumitomo Pharma America, INC. | $29.45 | 2025 | Orgovyx |
| Emd Serono, INC. | $27.25 | 2022 | |
| Exelixis INC. | $25.06 | 2025 | Cabometyx |
| Beone Medicines USA, INC. | $24.58 | 2025 | Brukinsa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $24.09 | 2023 | |
| Daiichi Sankyo INC. | $22.76 | 2025 | Vanflyta |
| Janssen Biotech, INC. | $20.90 | 2021 | |
| Lilly USA, LLC | $20.60 | 2024 | Retevmo, Verzenio, Jaypirca |
| Array Biopharma INC | $20.33 | 2021 | |
| Myovant Sciences INC. | $18.74 | 2022 | |
| Celgene Corporation | $18.57 | 2023 | Opdivo |
| Adaptive Biotechnologies Corporation | $18.46 | 2022 | |
| Astellas Pharma US INC | $14.68 | 2019 | |
| Acceleron Pharma, INC. | $12.54 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.